CA2289915A1 - Lignees de cellules tueuses naturelles et procedes d'utilisation - Google Patents

Lignees de cellules tueuses naturelles et procedes d'utilisation Download PDF

Info

Publication number
CA2289915A1
CA2289915A1 CA002289915A CA2289915A CA2289915A1 CA 2289915 A1 CA2289915 A1 CA 2289915A1 CA 002289915 A CA002289915 A CA 002289915A CA 2289915 A CA2289915 A CA 2289915A CA 2289915 A1 CA2289915 A1 CA 2289915A1
Authority
CA
Canada
Prior art keywords
cells
cell
vector
cytokine
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002289915A
Other languages
English (en)
Inventor
Hans Klingemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Conkwest Inc
Original Assignee
Hans Klingemann
Conkwest, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hans Klingemann, Conkwest, Inc. filed Critical Hans Klingemann
Priority claimed from PCT/US1998/008672 external-priority patent/WO1998049268A1/fr
Publication of CA2289915A1 publication Critical patent/CA2289915A1/fr
Abandoned legal-status Critical Current

Links

CA002289915A 1997-04-30 1998-04-30 Lignees de cellules tueuses naturelles et procedes d'utilisation Abandoned CA2289915A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9716397P 1997-04-30 1997-04-30
US60/045,885 1997-04-30
PCT/US1998/008672 WO1998049268A1 (fr) 1997-04-30 1998-04-30 Lignees de cellules tueuses naturelles et procedes d'utilisation

Publications (1)

Publication Number Publication Date
CA2289915A1 true CA2289915A1 (fr) 1998-11-05

Family

ID=31713880

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002289915A Abandoned CA2289915A1 (fr) 1997-04-30 1998-04-30 Lignees de cellules tueuses naturelles et procedes d'utilisation

Country Status (1)

Country Link
CA (1) CA2289915A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110418839A (zh) * 2017-03-08 2019-11-05 南克维斯特公司 用于临床的修饰的NK-92 haNK003细胞

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110418839A (zh) * 2017-03-08 2019-11-05 南克维斯特公司 用于临床的修饰的NK-92 haNK003细胞
CN110418839B (zh) * 2017-03-08 2023-06-09 免疫生物公司 用于临床的修饰的NK-92haNK003细胞
US11753625B2 (en) 2017-03-08 2023-09-12 Immunitybio, Inc. Modified NK-92 haNK003 cells for the clinic

Similar Documents

Publication Publication Date Title
US10138462B2 (en) Natural killer cell lines and methods of use
US8034332B2 (en) Interleukin-secreting natural killer cell lines and methods of use
US11771719B2 (en) Methods and compositions for gene editing in hematopoietic stem cells
US5272082A (en) Cytotoxic T-ALL cell lines and uses therefor
Klingemann The NK-92 cell line—30 years later: its impact on natural killer cell research and treatment of cancer
CN115466726B (zh) 一种nk细胞的高效基因转导方案
CA2162732C (fr) Utilisation de cellules tall-104 modifiees pour le traitement du cancer et des maladies virales
Cesano et al. Use of a lethally irradiated major histocompatibility complex nonrestricted cytotoxic T-cell line for effective purging of marrows containing lysis-sensitive or-resistant leukemic targets [see comments]
US5702702A (en) Modified cytotoxic tall cell line and compositions and methods for manufacture and use thereof as therapeutic reagents for cancer
CA2289915A1 (fr) Lignees de cellules tueuses naturelles et procedes d'utilisation
US5683690A (en) Modified cytotoxic tall cell line and compositions and methods for manufacture and use thereof as therapeutic reagents for cancer
US5820856A (en) Modified TALL-104 cells to treat cancer
WO2023082640A1 (fr) Procédé d'amélioration de la durabilité d'une cellule immunitaire
Porrata et al. Graft engineering for autologous stem cell transplantation
ES2389984T3 (es) Tratamiento de tumores mediante preparaciones de linfocitos T
Candotti Gene therapy for immunodeficiency
Kennedy-Nasser et al. T cell therapies following hematopoietic stem cell transplantation: surely there must be a better way than DLI?
Sun et al. The effects of natural killer-cell depletion on ex vivo expansion of hematopoietic progenitor cells from umbilical cord blood
Wong Antileukemic activities of human bone marrow and blood cells after culture in interleukins-2,-7 and-12
Kataoka et al. In vitro induction of perforin mRNA and cytotoxic activities in human splenocytes by the streptococcal preparation, OK-432
Dougherty Molecular mechanisms regulating the accumulation and functional activity of tumour-associated macrophages
Kloosterman Graft-versus-leukemia: applicable in the treatment of leukemia with bone marrow transplantation?: preclinical studies in rat models relevant for human acute leukemia
Verfaiilie et al. BLOOD OR MARROW PROGENITORS AS AUTOGRAFT FOR CML

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20161104